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Perinatal asphyxia (PA) is a clinical condition brought by a birth temporary oxygen
deprivation associated with long-term damage in the corpus striatum, one of the
most compromised brain areas. Palmitoylethanolamide (PEA) is a neuromodulator well
known for its protective effects in brain injury models, including PA, albeit not deeply
studied regarding its particular effects in the corpus striatum following PA. Using
Bjelke et al. (1991) PA model, full-term pregnant rats were decapitated, and uterus
horns were placed in a water bath at 37◦C for 19 min. One hour later, the pups were
injected with PEA 10 mg/kg s.c., and placed with surrogate mothers. After 30 days,
the animals were perfused, and coronal striatal sections were collected to analyze
protein-level expression by Western blot and the reactive area by immunohistochemistry
for neuron markers: phosphorylated neurofilament-heavy/medium-chain (pNF-H/M) and
microtubule-associated protein-2 (MAP-2), and the astrocyte marker, glial fibrillary acidic
protein (GFAP). Results indicated that PA produced neuronal damage and morphological
changes. Asphyctic rats showed a decrease in pNF-H/M and MAP-2 reactive areas,
GFAP+ cells number, and MAP-2 as well as pNF-H/M protein expression in the striatum.
Treatment with PEA largely restored the number of GFAP+ cells. Most important, it
ameliorated the decrease in pNF-H/M and MAP-2 reactive areas in asphyctic rats.
Noticeably, PEA treatment reversed the decrease in MAP-2 protein expression and
largely prevented PA-induced decrease in pNF-H/M protein expression. PA did not affect
the GFAP protein level. Treatment with PEA attenuated striatal damage induced by PA,
suggesting its therapeutic potential for the prevention of neurodevelopmental disorders.
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HIGHLIGHTS:
- Palmitoylethanolamide ameliorated neuronal damage
induced by PA in rat striatum.
- Perinatal asphyxia did not alter the protein expression of
GFAP in rat striatum.
- Palmitoylethanolamide largely reversed the decrease in the
number of GFAP+ cells induced by PA in rat striatum.
INTRODUCTION
Perinatal asphyxia (PA) is a clinical condition characterized
by a transient disruption of oxygen availability, followed
by metabolism deficits during birth that increases the risk
of mortality and morbidity in neonates worldwide (Capani
et al., 2001; Romero et al., 2015). Nearly 2–6/1,000 live
births are estimated experiencing PA, rising to 10 times
higher in developing countries (McGuire, 2007; Morales et al.,
2011). Depending on the severity, the time elapsed from the
insult, and the degree of fetal maturity, several biological
processes are triggered after PA, like a decrease in the
expression of synaptic proteins, cytoskeletal alterations, and
protein aggregation (Herrera et al., 2017a). These events may
eventually impair cellular function and lead to death and a
proinflammatory response as secondary injury (Herrera et al.,
2017a). Along with the hippocampus, the corpus striatum is
one of the most vulnerable brain structures to PA, hypoxia
(HI), and neurodegenerative injuries, partly due to its critical
location in the mesolimbic and the corticostriatal circuits
(Calabresi et al., 2000; Looi and Walterfang, 2013; Rocha-Ferreira
and Hristova, 2016). Due to the neuronal loss and synaptic
structure alterations induced by PA in these brain regions
(Herrera et al., 2017a), 25% of the surviving newborns develop
several neurodevelopmental abnormalities, including intellectual
disability and autism spectrum disorders (Schieve et al.,
2014; Modabbernia et al., 2016), attention-deficit/hyperactivity
disorder (Perna and Cooper, 2012), schizophrenia (Pugliese et al.,
2019), and neurodegenerative disorders (Gupta et al., 2018).
Previous studies from our group using an animal model
of PA (Bjelke et al., 1991) showed that PA-induced alterations
are characterized by increased astrogliosis in the hippocampus
and dorsal striatum (Cebral et al., 2006; Saraceno et al., 2010;
Holubiec et al., 2017), reduced microtubule-associated protein
2 (MAP-2) level, and alterations in the phosphorylation of
high- (200 kDa) and medium- (160 kDa) molecular-weight
neurofilaments (pNF-H/M) in the hippocampus in 120-day-
old rats (P120, postnatal day 120) (Saraceno et al., 2010)
or 30-day-old rats (P30, postnatal day 30) (Herrera et al.,
2018). Importantly, MAP-2 is predominantly localized in
neuronal dendrites of the caudate, hippocampus, cerebral cortex,
Abbreviations: ANOVA, analysis of variance; CNS, central nervous
system; CO, carbon monoxide; GFAP, glial fibrillary acidic protein;
HI, hypoxia-ischemia; HIE, hypoxia-ischemia encephalopathy; MAP-2,
microtubule-associated protein-2; MPTP, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine; PEA, palmitoylethanolamide; PA, perinatal asphyxia; PPARα,
peroxisome proliferator-activated receptor alpha; pNF-H/M, phosphorylated
high/medium-molecular-weight NF.
and cerebellum of rodents, and its absence or diminished
expression is considered as a marker of neurodegenerative
disorders (Popp et al., 2009; Saraceno et al., 2012a; Romero
et al., 2017). Neurofilaments (NFs) are highly phosphorylated
proteins relevant to neuronal structure and function. Changes
in phosphorylation alter their antigenicity and are considered
a pathological hallmark of several neurodegenerative diseases
(Mink and Johnston, 2000). Another biological landmark
of neurodegeneration is the glial fibrillary acidic protein
(GFAP), abundantly present in astrocytes in the entire central
nervous system. Astroglial cells respond to brain injury
and other neurological perturbations undergoing “reactive
astrogliosis,” a process whereby they develop cellular hypertrophy
with a concomitant increase in GFAP expression, and glial
cell proliferation, indicative of neuroinflammatory processes
involved in several neurodegenerative diseases (Villapol et al.,
2008; Yang and Wang, 2015). There is an urgent need to
improve our understanding of PA, which has currently no
effective treatment and to advance in the development of effective
pharmacological therapies based on specific biological targets.
One month after a severe, 20-min PA, the rats developed
an alteration in the endocannabinoid system expression and
related acylethanolamide pathways (Blanco et al., 2015).
Palmitoylethanolamide (PEA) is an endogenous lipidic
neuromodulator related to endocannabinoids, acting as a
peroxisome proliferator-activated receptor alpha (PPARα) or
G protein-coupled receptor 55 (GPR55) agonist that elicits
anti-inflammatory, neuroprotective, and restorative properties
(Mattace Raso et al., 2014; Petrosino and Di Marzo, 2017)
in vitro (Avagliano et al., 2016), in animal models of both
neurodegeneration (Esposito et al., 2011, 2012, 2014; Herrera
et al., 2016) and hypoxia-ischemia (HI) (Fernandez-Lopez et al.,
2013; England et al., 2015), and in human patients as well (Orefice
et al., 2016). Interestingly, one study reported that natives from
Puno at about 3,830 m above sea level in Peru, having high
hemoglobinemia and low oxygen saturation, also exhibited a
high plasma concentration of PEA (Alarcon-Yaquetto et al.,
2017). This suggests that PEA might be involved in long-term
adaptation to chronic high-altitude hypoxia, likely preventing the
development of chronic mountain sickness (Alarcon-Yaquetto
et al., 2017). Compared with other acylethanolamides, PEA
showed stronger anti-inflammatory effects reducing PA-induced
astrogliosis in P30 rats’ hippocampus (Holubiec et al., 2018)
and preventing cortical neurons from HI-induced cell death
(Portavella et al., 2018). Moreover, PEA treatment during the
first hour of life in asphyctic P30 rats reduced hippocampal
histological degeneration and prevented the anxiety-like
behavior induced by PA (Herrera et al., 2018). However, the
protective effects of PEA in the striatum of asphyctic rats have
not been addressed. We hypothesized that PEA might counteract
PA-induced neuronal and glial striatal damage in P30 rats.
Therefore, this work aimed to investigate: (i) whether it is
possible detecting neuronal cytoskeletal and glial alterations in
the striatum of asphyctic P30 rats and (ii) if PEA administration
within the first hour of life could ameliorate these alterations
in P30 rats.
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MATERIALS AND METHODS
Animals
Sprague Dawley pregnant rats (mothers, n = 20) were obtained
from the central vivarium at the School of Veterinary Sciences,
University of Buenos Aires. Rats were maintained at 21 ± 2◦C
and 65% ± 5% air humidity with free access to food and water,
under a 12:12-h light/dark cycle (lights on 7:00 a.m.). Fifty-three
pups (and 20 mothers) were used in the study. Each animal
was used only once, and all efforts were made to minimize
the suffering of the animals and reduce the number of animals
used. All procedures were performed by the National Institute
of Health Guide for the Care and Use of Laboratory Animals
(Animal Welfare Assurance, A-3033-01/protocol #S01084) and
were approved by the Ethics Committee of our Institution
(CICUAL #4091/04).
Induction of PA
Fifty-three male rat pups were subjected to PA using an
experimental model (Bjelke et al., 1991), which produces
moderate to severe PA (Van de Berg et al., 2003; Galeano et al.,
2011) as we described previously (Capani et al., 2003, 2009;
Saraceno et al., 2010, 2012a,b; Blanco et al., 2015; Holubiec
et al., 2017; Herrera et al., 2018). The murine model of PA,
originally developed by Bjelke et al. (1991), has been widely used
(Barkhuizen et al., 2017; Herrera et al., 2017b) and accepted to
mimic this condition (Capani et al., 1997, 2003, 2009; Boksa and
El-Khodor, 2003; Saraceno et al., 2010, 2012a,b; Strackx et al.,
2010; Muñiz et al., 2014; Romero et al., 2015; Wakuda et al.,
2015; Herrera et al., 2018). The Bjelke model presents several
advantages such as follows: (a) asphyxia is produced at birth
(Capani et al., 2009); (b) acidosis, hypercapnia, and hypoxia are
present in the whole body, replicating a global asphyxia, which is
the most common type (Strackx et al., 2010); (c) it is non-invasive,
avoiding the effects of surgical procedures; and (d) since hypoxia
is produced in the whole body, it affects both brain hemispheres,
which makes this model more suitable for behavioral studies
(Arteni et al., 2010). The control group was represented by non-
fostered vaginally delivered pups, mimicking the clinical situation
(Herrera et al., 2018).
Neuroprotection Protocol
Fifty-three male rat pups received the respective treatment
within the first hour of life. PEA (0879/10, Tocris Bioscience,
Bristol, United Kingdom) was dissolved in vehicle (VHI),
a solution containing 1:1:8 dimethyl sulfoxide, Tween 80,
and NaCl and administered by subcutaneous injection in
a volume of 10 mg/kg (Herrera et al., 2018). This dose
has previously shown to be effective in animal models of
experimental spinal cord injury (Genovese et al., 2008), 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-inducedmodel of
Parkinson’s disease (Esposito et al., 2012), lipopolysaccharide-
induced neuroinflammation (Sayd et al., 2014), hippocampal
damage and behavioral disturbances induced by PA (Herrera
et al., 2018), and cognitive function impairment and astrogliosis
induced by neonatal anoxia/ischemia in rats (Holubiec et al.,
2018). A preparation similar to that used in this study inhibited
the response of mesolimbic dopamine neurons to nicotine in the
ventral tegmental area, suggesting the ability of PEA to cross the
blood-brain barrier in rats (Melis et al., 2008). Control groups
received the respective vehicle (VHI). The different groups were
marked and mixed in litters with a surrogate mother. After
weaning, rats were housed in cages of three to four animals from
the same group. Cesarean controls were not used since previous
studies revealed that this group did not present significant
differences with vaginal controls (Galeano et al., 2011; Blanco
et al., 2015). The selection of male animals is supported by the fact
that estrogens exert neuroprotective properties (Saraceno et al.,
2010). Four experimental groups were studied: rats subjected
to PA and injected with VHI (PA–VHI group, n = 15), rats
born vaginally (controls–CTL) and injected with VHI (CTL–
VHI group, n = 13), rats subjected to PA and injected with PEA
(PA+PEA group, n = 18), and rats born vaginally and injected
with PEA (CTL+PEA group, n = 7). Four animals were used as
controls each for immunolabeling and WB assays.
Tissue Fixation and
Immunohistochemistry
We evaluated PA-induced dorsal striatal damage in rats (n = 16)
at P30. This age fairly resembles 4–11 human years (Semple
et al., 2013), when the first signs of neurodevelopmental disorders
appear (Herrera-Marschitz et al., 2014). We studied the dorsal
neostriatum for its high sensitivity to hypoxic injury focusing on
the axon bundles found either in the matrix or the striosome
(Capani et al., 1997; Gerfen, 1989). Four animals per group
(four replicates) were used. Three sections were immunostained
for each analyzed brain. Rats were anesthetized with ketamine
40 mg/kg i.p. and xylazine 5 mg/kg i.p. and intracardially
perfused with 4% paraformaldehyde in a 0.1 M phosphate buffer
(pH 7.4) (Saraceno et al., 2016). The brains were immediately
removed, post-fixed in the 4% paraformaldehyde in 0.1 M
phosphate buffer (pH 7.4) solution at room temperature for 2 h,
and immersed in a 0.1 M phosphate buffer (pH 7.4) overnight
at 4◦C. Coronal dorsal striatum sections (sections at the coronal
plane, 50 µm thick) were cut using a Vibratome (VT 1000 S, Leica
Microsystems, Wetzlar, Germany). This well-set technique using
a 50-micron-thick vibratome section avoids embedding the tissue
in paraffin with the resulting decrease in the antigenicity, gaining
label specificity.
Immunohistochemistry was performed on free-floating
sections under moderate shaking. Before staining, the sections
were incubated 10 min in 3% hydrogen peroxide to quench
endogenous peroxidases. After three washing steps in 0.1 M
phosphate buffer (pH 7.4), non-specific antibody binding
sites were blocked with using 0.3% normal goat serum.
Free-floating sections were incubated overnight at 4◦C
with anti-MAP-2 (1:250, polyclonal rabbit-IgG; ab32454,
Abcam, Cambridge, United Kingdom); anti-pNF-H/M, which
recognizes the KSP repeats of the phosphorylated form (1:500,
monoclonal mouse-IgG; MAB1592, Millipore, Burlington,
VT, United States); or anti-GFAP (1:200, monoclonal rabbit-
IgG; Cell-Marque, Sigma-Aldrich Company, Code. EP672Y).
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After several washes, sections were incubated for 1 h at room
temperature with secondary antibodies (biotinylated anti-
mouse-IgG, 1:500, BA9200, or biotinylated anti-rabbit-IgG,
1:500, BA-1000; Vector, Burlingame, VT, United States).
The streptavidin/horseradish peroxidase detection system
(1:500, K0609; Dako, Santa Clara, CA, United States) was
used for antigen staining according to the manufacturer’s
recommendations. Sections were incubated with the substrate
diaminobenzidine (D3939; Sigma-Aldrich Company, St. Louis,
MO, United States) for 2 min at room temperature. Light
microscopic images were obtained using a Leica microscope
(Herrera et al., 2018).
Morphometric Analysis
The reactive area for pNF-H/M and MAP-2 was estimated using
the Image J program (Image J 1.41o; NIH, United States) as
described previously, and expressed as a percentage (Herrera
et al., 2018). One hundred fifty by 150 µm was sampled in
each photo to estimate the percentage of reactive area for pNF-
H/M and MAP-2 using the Image J program (Image J 1.41o;
NIH, United States). We analyzed the dorsal striatum because
it is one of the most affected areas by PA insult (Holubiec
et al., 2017). The number of GFAP immunoreactive astrocytes
was manually estimated in the dorsal striatum. Eighty counting
frames were assessed per animal. A blind observer selected
five fields for each sector from three sections of the dorsal
striatum. Triplicates were performed to estimate the percentage
of the reactive area and the number of GFAP immunoreactive
astrocytes. The NFs and microtubules were expressed as the
percentage of the relative area since they cannot be individually
counted. Conversely, GFAP was expressed as the absolute
value since GFAP labeling allows for visualization per astrocyte
and can be counted.
Western Blot
Western blot analysis was performed using four animals per
treatment (n = 16, four replicates) by triplicate per brain.
The rats were euthanized by decapitation, and the corpus
striatum was dissected and homogenized in ice-cold lysis buffer,
containing 10 mM Tris–HCl at pH 7.4, 10 mM NaCl, 3 mM
MgCl2, 0.1% Triton X-100, and protease inhibitors. Tissues were
thawed on ice and centrifuged at 14,000 rpm for 15 min at 4◦C.
The protein concentration was analyzed using the Bradford
solution (500-0201; Bio-Rad, Richmond, CA, United States)
and bovine serum albumin as the standard (Herrera et al.,
2018). Total protein (80 µg) was diluted in buffer [0.3 M
Tris–HCl (pH 7), 5% glycerol, 5% SDS, 1 mM EDTA, 0.1%
bromophenol blue] and subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis. Polyvinylidene difluoride
membranes containing the transferred proteins were blocked
with 5% non-fat milk powder and 1% bovine serum albumin
in a Tris-buffered saline solution containing 0.05% Tween 20.
The membranes were incubated overnight at 4◦C with the
following primary antibodies: anti-MAP-2 (1:1,000, polyclonal
rabbit-IgG; ab32454, Abcam, Cambridge, United Kingdom),
anti-PNF-H/M (1:500, monoclonal mouse-IgG; MAB1592,
Millipore, Burlington, VT, United States), or anti-GFAP (1:1,000,
monoclonal mouse-IgG; SC-33673, Santa Cruz Biotechnology),
and anti-glyceraldehyde-3-phosphate dehydrogenase (1:3,000,
rabbit-IgG, G9545; Sigma-Aldrich Company, St. Louis, MO,
United States) as the loading control. Next, the membranes
were incubated with rabbit and mouse, secondary horseradish
peroxidase-conjugated antibodies (1:3,000, 170-6515, and
170-6516, respectively; Bio-Rad, Richmond, CA, United States)
for 1 h at room temperature. The protein bands were detected
using an enhanced chemiluminescence Western blotting analysis
system (clarity Western enhanced chemiluminescence substrate,
1705061; Bio-Rad, Richmond, CA, United States). The films were
scanned, and the optical density of protein bands was quantified
using Gel-Pro Analyzer 3.1.00.00 (Media Cybernetics).
Statistical Analysis
Results are expressed as means ± SEM. Normal distribution was
checked using the Shapiro–Wilk test. The data were submitted
to a two-way ANOVA. Factors were the birth condition (PA
or CTL) and treatment (PEA or VHI). When birth condition-
treatment interaction was significant, multiple comparisons were
performed using Tukey’s t-test. A p< 0.05 was conventionally set
as the significance level. Statistical analysis was carried out using
GraphPad PrismTM 7 software.
RESULTS
Effect of PEA Treatment on PA-Induced
Alterations in pNF-H/M Tissue
Immunostaining and Protein Expression
at P30
The phosphorylation of pNF-H/M, a measure of axonal
dysfunction and degeneration, was analyzed by immunostaining
at P30 in the rat dorsal striatum. Figure 1A shows PA-induced
morphological changes in a representative striatal section
immunostained for pNF-H/M. The percentage of reactive area
for pNF-H/M was dependent on birth condition and treatment
[F(1,8) = 74,552, p < 0.0001; F(1,8) = 15,608, p < 0.0001,
respectively], showing between-interaction [F(1,8) = 15,639,
p < 0.0001]. Post hoc analysis revealed that the reactive area
for pNF-H/M decreased due to PA (PA–VHI) (p < 0.0001,
Figure 1B), and that it was largely yet not completely attenuated
by PEA treatment (PA+PEA) (p < 0.0001, Figure 1B).
Consistently, at P30, striatal protein expression for pNF-H/M
was dependent on birth condition and treatment [F(1,8) = 122.3,
p < 0.0001; F(1,8) = 8.002, p = 0.0222, respectively], also showing
between-interaction [F(1,8) = 10.18, p = 0.0128]. Post hoc analysis
confirmed a decrease in pNF-H/M protein expression in the PA–
VHI group (p < 0.0001), largely yet not completely ameliorated
by PEA treatment (PA+PEA) (p = 0.0119, Figure 1C) (p = 0.0024,
Figure 1C). Finally, pNF-H/M reactive area and protein level
were not different between the control group treated with either
vehicle or PEA [CTL–VHI vs. CTL+PEA, p = 0.9997 (reactive
area); p > 0.9937 (protein level); Figures 1B,C]. For more detail,
please see Supplementary Figures 1 and 2.
Frontiers in Neuroscience | www.frontiersin.org 4 January 2020 | Volume 13 | Article 1345
fnins-13-01345 December 20, 2019 Time: 16:13 # 5
Udovin et al. PEA Neuroprotection in Perinatal Asphyxia
FIGURE 1 | Phosphorylated neurofilament-heavy/medium-chain (pNF-H/M) immunostaining and protein level in the rat striatum in the experimental groups.
(A) Representative images of dorsal striatum immunostained for pNF-H/M. The white arrow indicates the positive immunostaining area for pNF-H/M; AF indicates
the axonal fascicles. Strictly dorsal striatum was used for immunohistochemistry due to its high vulnerability to hypoxia. Scale bar: 50 µm. (B) Percentage of
pNF-H/M reactive area. (C) Optical density of bands showing pNF-H/M protein expression level. Bars and error bars represent the mean ± SEM. Two-way ANOVA
followed by Tukey’s post hoc test. ∗∗∗∗p < 0.0001, PA–VHI vs. CTL–VHI, ••••p < 0.0001, and •p < 0.05, PA–VHI vs. PA+PEA; ####p < 0.0001 and ##p < 0.005,
PA+PEA vs. CTL–VHI. PEA did not affect either pNF-H/M immunostaining or protein expression as there was no difference between CTL+PEA and CTL–VHI groups.
CTL–VHI, control rats treated with vehicle; PA–VHI, rats subjected to PA and treated with vehicle; PA+PEA, rats subjected to PA and PEA treatment; CTL+PEA,
control rats treated with PEA; PEA, palmitoylethanolamide.
Effects of PEA Treatment in Dendritic
Cytoskeleton Alterations and MAP-2
Tissue Immunostaining and Protein
Expression at P30 After PA
Since PA affected neuronal cytoskeleton, we also studied
morphological changes through immunostaining of the dendrite-
specific marker MAP-2 in the rat dorsal striatum at P30.
Morphological changes were observed due to PA (PA–VHI)
(Figure 2A). The MAP-2 reactive area was dependent on both
birth condition and treatment [F(1,8) = 16,629, p < 0.0001;
F(1,8) = 17,810, p < 0.0001, respectively]. Birth condition-
treatment interaction was also significant [F(1,8) = 17,711,
p < 0.0001]. Post hoc analysis revealed a decrease in the
percentage of MAP-2 reactive area in the PA–VHI group
compared with the control group (CTL–VHI) (p < 0.0001,
Figure 2B), which was fully reversed by PEA treatment
(PA+PEA) (p < 0.0001, Figure 2B) reaching control values
(p = 0.0515 for reactive area; p = 0.9974 for protein
level, Figure 2C). The analysis of MAP-2 protein expression
in the rat striatum at P30 confirmed these findings. The
protein level of MAP-2 was dependent on birth condition
and treatment [F(1,8) = 40.14, p = 0.0002; F(1,8) = 36.83,
p = 0.0003, respectively], with significant between-interaction
[F(1,8) = 36.09, p = 0.0003]. The post hoc analysis confirmed that
PA (PA–VHI group) decreased MAP-2 protein level (p < 0.001,
Figure 2C), which was fully restored to control values by
PEA treatment (PA+PEA) (p < 0.001, Figure 2C), reaching
control values (p = 0.9974, Figure 2C). Finally, MAP-2 reactive
area protein level was not different between the control group
treated with either vehicle or PEA (CTL–VIH vs. CTL+PEA
p = 0.9932 for the reactive area, p > 0.9999 for protein level)
(Figures 2B,C, respectively).
GFAP Immunostaining and Protein
Expression at P30 After PA: Protective
Effect of PEA Treatment
We used immunohistochemistry and Western blot to analyze
glial response to PA injury and PEA treatment in the rat dorsal
striatum at P30 (n = 16). Figure 3A shows a representative
striatal section immunostained for GFAP+ immunoreactive
astrocytes. The number of GFAP+ immunoreactive astrocytes
was dependent on birth condition and treatment [F(1,56) = 58.73,
p < 0.0001; F(1,56) = 16.44, p = 0.0002, respectively] showing
between-interaction [F(1,56) = 19.4, p < 0.0001]. The post hoc
analysis revealed that PA (PA–VHI) reduced the number of
GFAP+ immunoreactive astrocytes compared with the control
group (CTL–VHI) (p < 0.0001, Figure 3B). This decrease
was, to some extent, reversed by PEA treatment (PA+PEA)
(p < 0.0001, Figure 3B) without reaching control values
(p = 0.0048, Figure 3B). Also, the number of GFAP+
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FIGURE 2 | Microtubule-associated protein (MAP-2) immunostaining and protein level in the rat striatum in the experimental groups. (A) Representative images of
the dorsal striatum immunostained for MAP-2. The figure shows MAP-2 immunostaining in the dorsal striatum; AF indicates the axonal fascicles. Scale bar: 50 µm.
The main-image marked rectangular areas are shown magnified in the corresponding upper right margin. The black arrow indicates the positive immunostaining area
for MAP-2. Scale bar: 25 µm. (B) Percentage of MAP-2 reactive area. (C) Optical density of bands showing for MAP-2 protein expression level. Bars and error bars
represent the mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test. ∗∗∗∗p < 0.0001 and ∗∗∗p < 0.001, PA–VHI vs. CTL–VHI; ••••p < 0.0001 and
•••p < 0.001, PA–VHI vs. PA+PEA. PEA had no effect on either MAP-2 immunostaining or protein expression level as there was no difference between CTL+PEA
and CTL–VHI groups. No difference was found in MAP-2 immunostaining or protein expression level between PA+PEA and CTL–VHI groups. CTL–VHI, control rats
treated with vehicle; PA–VHI, rats subjected to PA and treated with vehicle; PA+PEA, rats subjected to PA and PEA treatment; CTL+PEA, control rats treated with
PEA.
immunoreactive astrocytes was not different between vehicle-
treated (CTL–VHI) or PEA-treated control rats (CTL+PEA)
(p = 0.9946, Figure 3B). However, neither birth condition
or treatment affected GFAP expression [F(1,8) = 0.04421,
p = 0.8387; F(1,8) = 0.01157, p = 0.917, respectively] nor
between-interaction was observed [F(1,8) = 0.002636, p = 0.9603,
Figure 3C].
DISCUSSION
Present findings show PA-induced morphological alterations like
dendritic damage (MAP-2 reduction), axonal injury (pNF-H/M
reduction), and a decrease in the number of astrocytes (GFAP+
cells) in the dorsal corpus striatum at P30. The effects on both
MAP-2 and pNF-H/M were confirmed by Western blot. The
MAP-2 is a commonly used biomarker to assess the extension
and distribution of dendritic cytoskeletal degeneration induced
by hypoxia-ischemia (HI) (Mink and Johnston, 2000; Kühn
et al., 2005; Graham et al., 2018). Immunoreactivity for MAP-2
decreased in the human post-mortem hippocampus and cerebral
cortex after carbon monoxide (CO) exposure (Kühn et al.,
2005). Transient or permanent middle cerebral artery occlusion
followed by reperfusion reduced MAP-2 expression mainly in
rat striatum and neocortex (Popp et al., 2009). Also, MAP-
2 immunostaining decreased in the cerebral cortex, caudate,
and thalamus in a perinatal stroke rat model (Malinak and
Silverstein, 1996), and in the cerebral cortex of neonatal rats
after transient cerebral HI (Blomgren et al., 1995). In our
study, PA induced a marked decrease both in protein level
and immunoreactivity of MAP-2 in rat striatum at P30. In
agreement, previous studies from our laboratory reported a
significant reduction of MAP-2 at P30 in the striatum (Saraceno
et al., 2012a). Similar results were found in the hippocampus
at the same time point (Herrera et al., 2018), and later at
P120 (Saraceno et al., 2010). This reduction of MAP-2 could
be related to a decrease of adenosine triphosphate synthesis
triggered by the low availability of oxygen after the hypoxic event
(Islam and Burns, 1980).
This study also shows a substantial decrease in protein level
and immunoreactivity of pNF-H/M in the corpus striatum in
response to PA at P30 that might result from calpain, a calcium-
dependent protease largely distributed in the brain, activation
(Schlaepfer, 1987) by hypoxia (Stys and Jiang, 2002). Likewise, a
decrease in volume and a loss of phosphorylated NFs were found
in the corpus callosum and the internal capsule in experimental
cerebral palsy (Drobyshevsky et al., 2007). Although we have
recently demonstrated that PA was associated with an increase
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FIGURE 3 | GFAP+ cells and protein expression level in the rat striatum. (A) Representative images of the dorsal striatum immunostained for glial fibrillary acidic
protein (GFAP). The white arrow shows an astrocyte immunostained for GFAP. Scale bar: 50 µm. (B) Number of the GFAP+ cells measured per experimental group.
(C) Optical density of the bands for GFAP protein expression level. Bars and error bars represent mean ± SEM. Two-way ANOVA followed by Tukey’s post hoc test.
∗∗∗∗p < 0.0001, PA–VHI vs. CTL–VHI, ••••p < 0.0001, PA–VHI vs. PA+PEA and ##p < 0.005, PA+PEA vs. CTL–VHI. PEA had no effect on GFAP+ immunostaining
as there was no difference between CTL+PEA and CTL–VHI groups. Neither PA nor PEA affected GFAP protein level. CTL, control rats treated with vehicle; PA–VHI,
rats subjected to PA and treated with vehicle; PA+PEA, rats subjected to PA and PEA treatment; CTL+PEA, control rats treated with PEA.
in protein level and pNF-H/M immunoreactivity in the CA1
hippocampus at P30 (Herrera et al., 2018), the level of pNF-H
varies depending on the brain region, being low in the cerebral
cortex and intermediate to high in the large-diameter brain stem
axons, cerebellum, thalamus, subcortical white matter, and basal
ganglia, as well as in varied pathological conditions (Shaw et al.,
2005; Drobyshevsky et al., 2007; Anderson et al., 2008; Guy et al.,
2008; Lewis et al., 2008; Boylan et al., 2009; Herrera et al., 2018).
Bearing this in mind, the choice of different tissue sources may
account for the discrepancies between studies, making further
research necessary.
Unlike the consistency found for either pNF-H/M or
MAP-2, discrepant findings were observed between a change
in GFAP measured as the percentage of the reactive area
(immunohistochemistry and the lack of change in optical density
in the amount of protein (Western blot). The difference in the
anatomical region used in each case might well account for
the discrepancy. The dorsal striatum, the most vulnerable area
to hypoxia, was used for immunohistochemical determinations.
Conversely, due to methodological issues, the entire corpus
striatum, both ventral and dorsal, was used for Western blot
analysis, likely what might dilute any changes that might have
eventually been observed otherwise. On top of this, negligible
differences might have gone undetected due to insufficient
sensitivity in the Western blot determinations.
Notwithstanding that GFAP did not appear as an early marker
of hippocampal damage after PA, we assessed the number of
GFAP+ astrocytes in the dorsal striatum based on our previously
reported PA-induced changes in GFAP immunostaining in this
region at P30 (Holubiec et al., 2017). Presently, PA induced
a remarkable decrease in the number of astroglial cells. This
finding likely attributable to astrocytic death might precede
neuronal loss and inflammatory reaction according to previous
evidence (Villapol et al., 2008; Hostenbach et al., 2014; Romero
et al., 2014). In perinatal ischemia followed by reperfusion, the
proapoptotic protein Bax was up-regulated in GFAP+ astrocytes,
particularly in the peri-infarct region in the cortex at P30
post-ischemia (Benjelloun et al., 1999; Villapol et al., 2008),
and apoptotic and necrotic morphological features are seen in
the same astrocytes 12–24 h after oxygen-glucose deprivation,
accompanied by autophagosomes that appear in the astrocytes’
cytoplasm in both ischemic cortices (Xu and Zhang, 2011).
After neonatal ischemia, these dying reactive astrocytes might
participate in the ongoing deleterious process and promote the
formation of cystic lesions as clinically observed in the newborn
brain (Villapol et al., 2008). However, our results in GFAP
immunostaining were not confirmed by Western blot. Therefore,
further studies are necessary to clarify this point.
Treatment with PEA (10 mg/kg) within the first hour of
life attenuated PA-induced dendritic and axonal cytoskeletal
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damage in the dorsal striatum at P30 according to the change
in MAP-2 and pNF-H/M both immunostaining and protein
levels, respectively. In addition, PEA treatment prevented the
decrease in the number of GFAP+ cells in the PA dorsal striatum
at P30. Recently, we reported that PEA neuroprotected from
dendritic and axonal cytoskeletal alterations induced by PA in
the hippocampus (Herrera et al., 2018). Interestingly, Blanco
et al. (2015) showed that PA induced a substantial decrease in
the protein level of the PEA receptor, PPARα, and in N-acyl
phosphatidylethanolamine-specific phospholipase D (Blanco
et al., 2015), an enzyme that synthesizes acylethanolamides
like PEA (Harrison et al., 2014) also at P30. This reduction
could lead to dysregulation and a decrease in endocannabinoids
level, inhibiting PPARα activity (Blanco et al., 2015). Then,
reasonably enough, the exogenous administration of PEA may be
responsible for the protective effects reported in this study.
Furthermore, our findings agree with previous reports on
the protective effects of PEA in experimental neurodegeneration
(Skaper et al., 1996; Esposito et al., 2012; Scuderi et al., 2014;
Herrera et al., 2016). PEA protected from the decrease in MAP-
2 expression induced by amyloid peptides (Scuderi et al., 2014;
Tomasini et al., 2015) and by MPTP in an animal model of
Parkinson’s disease (Esposito et al., 2012). Similarly, PEA could
prevent MAP-2 reduction after hypoxia (Kühn et al., 2005;
Fernandez-Lopez et al., 2013; England et al., 2015).
All in all, the experimental evidence supports the protective
role of PEA against neuronal damage in several brain injuries,
including PA-induced brain damage. Consistently with a vast
number of studies, the present work reinforces the evidence of the
neuroprotective effects of PEA against HI in the corpus striatum,
a vulnerable brain structure to HI injuries, fostering our further
investigation of the mechanisms involved.
A next study should examine the ultrastructural effects of
PEA treatment regarding its presently reported effects on the
expression of pNF-H/M and MAP-2, ruling out any possible bias
in the interpretation of optical microscopy images.
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